Showing 1341-1350 of 21414 results for "".
- $1.9M Initiative Supports Early-Career Lupus Researchhttps://reachmd.com/news/19m-initiative-supports-early-career-lupus-research/2486503/Key Takeaways: The announcement describes a joint Lupus Research Alliance–Rheumatology Research Foundation partnership funding round focused on early-career lupus and rheumatology research. Five named investigators and their project titles are listed,
- Systematic Review Examines Vaginal Laser and Radiofrequency for Stress Urinary Incontinencehttps://reachmd.com/news/systematic-review-examines-vaginal-laser-and-radiofrequency-for-stress-urinary-incontinence/2486518/In a systematic review and meta-analysis published in International Urogynecology Journal, investigators reported that energy-based devices may offer modest short-term symptom improvement for women with stress urinary incontinence compared with sham treatment. David Lukanović, Gee
- Tapinarof Shows Rapid Itch and Skin Improvement in Atopic Dermatitishttps://reachmd.com/news/tapinarof-shows-rapid-itch-and-skin-improvement-in-atopic-dermatitis/2486493/New pooled Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the rapid onset and consistent efficacy of tapinarof cream 1% (VTAMA; Organon) in patients with moderate-to-severe atopic dermatitis (AD), including children as young as 2 years. Th
- TYK2-JAK1 Inhibitor Treatment Promising for Individuals with Refractory Dermatomyositishttps://reachmd.com/news/tyk2-jak1-inhibitor-treatment-promising-for-individuals-with-refractory-dermatomyositis/2486481/Results from the Phase 3 VALOR trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting revealed that individuals with re
- AI-based CCTA plaque quantification vs IVUS: INVICTUS Registry abstracthttps://reachmd.com/news/ai-based-ccta-plaque-quantification-vs-ivus-invictus-registry-abstract/2486488/The INVICTUS Registry abstract describes an automated artificial intelligence workflow for coronary CT angiography plaque quantification being assessed
- AAD 2026: New Study Highlights Dual-Action Antioxidant Serum for UV-Induced Skin Protectionhttps://reachmd.com/news/aad-2026-new-study-highlights-dual-action-antioxidant-serum-for-uv-induced-skin-protection/2486463/New research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting highlights the potential of a multifunctional antioxidant serum, AOX2.0, to protect human skin from ultraviolet (UV)-induced damage while supporting epidermal recovery. The study examined how oxidative stress
- Combination Therapy Improves Outcomes in Psoriatic Arthritis With Obesityhttps://reachmd.com/news/combination-therapy-improves-outcomes-in-psoriatic-arthritis-with-obesity/2486455/Combination therapy with ixekizumab and tirzepatide demonstrated superior disease control compared with ixekizumab alone in adults with psoriatic arthritis (PsA) and overweight or obesity, according to Phase 3b TOGETHER-PsA results presented by Joseph F. Merola, MD, MMSc, at the American Academy
- IL-15 Blockade Plus Phototherapy Shows Promise in Vitiligohttps://reachmd.com/news/il-15-blockade-plus-phototherapy-shows-promise-in-vitiligo/2486454/Targeting IL-15 with ordesekimab in combination with narrowband ultraviolet B (nbUVB) phototherapy led to greater repigmentation in patients with non-segmental vitiligo, according to results from a randomized, placebo-controlled trial presented by Brett King, MD, PhD, at the American Academy of D
- Dersimelagon Improves Sunlight Tolerance in EPP and XLPhttps://reachmd.com/news/dersimelagon-improves-sunlight-tolerance-in-epp-and-xlp/2486452/Dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist, significantly improved sunlight tolerance in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), according to Phase 3 INSPIRE trial results presented by Amy Dickey Yeung, MD, at the American Academy of
- Roflumilast Cream Shows Safety and Efficacy in Infants With Atopic Dermatitishttps://reachmd.com/news/roflumilast-cream-shows-safety-and-efficacy-in-infants-with-atopic-dermatitis/2486449/Roflumilast cream 0.05%, a topical phosphodiesterase 4 (PDE4) inhibitor, demonstrated favorable safety and clinically meaningful efficacy in infants with atopic dermatitis (AD), according to results from the Phase 2 INTEGUMENT-INFANT study presented by Lawrence F. Eichenfield, MD, at the American